Prevalence of and Factors Associated With Metabolic Syndrome in Schizophrenia

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2012 by Chiang Mai University
Sponsor:
Information provided by (Responsible Party):
Sirijit Suttajit, Chiang Mai University
ClinicalTrials.gov Identifier:
NCT01587521
First received: April 26, 2012
Last updated: September 22, 2012
Last verified: September 2012
  Purpose

Patients with schizophrenia are more likely to have metabolic syndrome compared to general population. The criterion for metabolic syndrome in Asian people including: elevated waist circumference (male ≥ 90cm, female ≥ 80cm), elevated triglycerides ≥ 150mg/dL, reduced HDL cholesterol: male < 40mg/dL, female < 50mg/dL, elevated blood pressure: ≥ 130/85 mmHg, elevated fasting glucose: ≥ 100mg/dL. Several factors have been found to be associated with metabolic syndrome in schizophrenia, e.g. age, antipsychotic drugs, smoking, family history of metabolic disorder, stress, and quality of life.

However, little is known about the prevalence of and factors associated in Asian. This study aimed to:

  1. Identify the prevalence of metabolic syndrome in patients with schizophrenia.
  2. Identify the factors associated with metabolic syndrome in patients with schizophrenia.

Condition
Metabolic Syndrome
Quality of Life
Depression

Study Type: Observational
Study Design: Time Perspective: Cross-Sectional
Official Title: Prevalence of and Factors Associated With Metabolic Syndrome in Patients With Schizophrenia

Resource links provided by NLM:


Further study details as provided by Chiang Mai University:

Estimated Enrollment: 80
Study Start Date: January 2012
Estimated Study Completion Date: November 2012
Detailed Description:

Patients with schizophrenia are more likely to have metabolic syndrome compared to general population. The criterion for metabolic syndrome in Asian people including: elevated waist circumference (male ≥ 90cm, female ≥ 80cm), elevated triglycerides ≥ 150mg/dL, reduced HDL cholesterol: male < 40mg/dL, female < 50mg/dL, elevated blood pressure: ≥ 130/85 mmHg, elevated fasting glucose: ≥ 100mg/dL. Several factors have been found to be associated with metabolic syndrome in schizophrenia, e.g. age, antipsychotic drugs, smoking, family history of metabolic disorder, stress, and quality of life.

However, little is known about the prevalence of and factors associated in Asian. This study aimed to:

  1. Identify the prevalence of metabolic syndrome in patients with schizophrenia.
  2. Identify the factors associated with metabolic syndrome in patients with schizophrenia.

Method This study is a cross-sectional study conducting at the Faculty of Medicine, Chiang Mai University. Eighty participants will be recruited with the inclusion criteria of having diagnosed with schizophrenia according to DSM-IV-TR and aged 18 years or over. The exclusion criterion is having organic brain syndrome.

Measurements PANSS CDSS WHOQOL-BREF-THAI

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Participants diagnosed with schizophrenia

Criteria

Inclusion Criteria:

  • Diagnosis of schizophrenia according to DSM-IV-TR
  • Aged 18 years-old or over

Exclusion Criteria:

  • Having organic brain syndromes
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01587521

Contacts
Contact: Sirijit Suttajit, MD 66-53-945422

Locations
Thailand
Chiang Mai University Recruiting
Chiang Mai, Thailand, 50200
Sponsors and Collaborators
Chiang Mai University
Investigators
Study Director: Sirijit Suttajit, MD. MSc. Chiang Mai University
  More Information

No publications provided

Responsible Party: Sirijit Suttajit, Assistant professor, Chiang Mai University
ClinicalTrials.gov Identifier: NCT01587521     History of Changes
Other Study ID Numbers: PSY-11-07-26A-12
Study First Received: April 26, 2012
Last Updated: September 22, 2012
Health Authority: Thailand: Ethical Committee

Keywords provided by Chiang Mai University:
Metabolic syndrome
Prevalence
Quality of life
Depression
Antipsychotics

Additional relevant MeSH terms:
Depressive Disorder
Schizophrenia
Mood Disorders
Mental Disorders
Schizophrenia and Disorders with Psychotic Features
Glucose Metabolism Disorders
Metabolic Diseases
Depression
Metabolic Syndrome X
Behavioral Symptoms
Insulin Resistance
Hyperinsulinism

ClinicalTrials.gov processed this record on August 28, 2014